Search results
Results from the WOW.Com Content Network
Various authors have suggested that thyrotoxic myopathy is a result of the weight loss and generalized asthenia associated with hyperthyroidism. Muscle involvement has been reported to occur in about 80% of thyrotoxic patients (see section #Epidemiology ), [ 7 ] and the most common causes of hyperthyroidism are Graves’ disease , toxic ...
Thyrotoxic periodic paralysis (TPP) is a rare condition featuring attacks of muscle weakness in the presence of hyperthyroidism (overactivity of the thyroid gland). Hypokalemia (a decreased potassium level in the blood) is usually present during attacks.
The same three treatments used with humans are also options in treating feline hyperthyroidism (surgery, radioiodine treatment, and anti-thyroid drugs). There is also a special low iodine diet available that will control the symptoms providing no other food is fed; Hill's y/d formula, when given exclusively, decreases T4 production by limiting ...
Thyroid diseases are highly prevalent worldwide, [10] [11] [12] and treatment varies based on the disorder. Levothyroxine is the mainstay of treatment for people with hypothyroidism, [ 13 ] while people with hyperthyroidism caused by Graves' disease can be managed with iodine therapy, antithyroid medication, or surgical removal of the thyroid ...
It was first identified in 1966 at the Mayo Clinic, by A.G. Engel, [2] and that same year W.K. Engel and J.S. Resnick noted another case that they elaborated in 1975. [3] [4] The diagnosis of the disease rests on subacutely evolving weakness after age 40, normal to low CK level, a myopathic EMG with fibrillations, and often a monoclonal gammopathy.
Treatment of the hyperthyroidism results in complete recovery of the myopathy. [7] ANIM caused by vitamin D deficiency can easily be resolved by taking vitamin supplements and increasing one's exposure to direct sunlight. [8] Pain can be managed through massaging affected areas and the use of nonsteroidal anti-inflammatory drugs (NSAIDs).
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...
Anderson and colleagues from St Thomas' Hospital, London, were the first to mention a case with possible clinical findings of LEMS in 1953, [12] but Edward H. Lambert, Lee Eaton, and E.D. Rooke at the Mayo Clinic were the first physicians to substantially describe the clinical and electrophysiological findings of the disease in 1956.